Holm L E, Alinder I
Acta Med Scand. 1982;211(6):489-92. doi: 10.1111/j.0954-6820.1982.tb01987.x.
Between 1969 and 1979 a course of either propylthiouracil or carbimazole was given to 102 patients with Graves' disease. Ten of the patients discontinued the therapy because of adverse reactions or persisting symptoms, and 40 relapsed at some time after cessation of the therapy, giving a proportion of total failures of 49%. The proportion of such failures increased from 45% in 1969-72 to 57% in 1973-79. The probability of relapse was significantly higher in 1973-79 than in the earlier period (p less than 0.01). Patients aged 30-39 years had the highest proportion of failures (55%), but the mean time until relapse (6 months) was shortest in patients older than that. Adverse reactions--agranulocytosis, leukopenia, urticaria and elevated serum levels of liver enzymes--were seen in 12 patients. Six patients developed hypothyroidism after a mean time of 3.5 years after termination of thionamide therapy.
1969年至1979年间，102例格雷夫斯病患者接受了丙硫氧嘧啶或卡比马唑治疗。10例患者因不良反应或症状持续而中断治疗，40例患者在治疗停止后的某个时间复发，总失败比例为49%。此类失败比例从1969 - 1972年的45%增至1973 - 1979年的57%。1973 - 1979年复发概率显著高于早期（p小于0.01）。30 - 39岁患者失败比例最高（55%），但年龄大于该年龄段的患者复发平均时间最短（6个月）。12例患者出现不良反应——粒细胞缺乏症、白细胞减少、荨麻疹和血清肝酶水平升高。6例患者在硫酰胺类药物治疗终止后平均3.5年出现甲状腺功能减退。
